Lytix Biopharma is a pioneering clinical-stage biotech company utilizing a groundbreaking technology platform that harnesses host-defense peptide-derived molecules to eradicate cancer cells and stimulate the immune system. By targeting the inherent challenges in cancer treatment, our goal is to enhance outcomes for cancer patients. In contrast to conventional immunotherapy approaches that face limitations due to tumor heterogeneity and immune response variations, Lytix Biopharma's innovative molecules effectively eliminate cancer cells, including resistant ones, and expose their internal components to the immune system.

This process triggers a robust and enduring systemic T-cell response by activating tumor antigen presenting cells, ultimately surmounting tumor heterogeneity. Our molecules have broad applicability across various cancer types and treatment modalities, be it as standalone therapy or in combination regimens. Join us in our mission to revolutionize cancer treatment.

Visit us to learn more